Treatment of excessive daytime sleepiness in patients with Parkinson's disease with modafinil.
Nieves AV, Lang AE.
Morton and Gloria Shulman Movement Disorders Center
Toronto Western Hospital, Toronto, Ontario, Canada; and
University of Medicine & Dentistry of New Jersey,
Robert Wood Johnson Medical School,
New Brunswick, New Jersey, USA
Clin Neuropharmacol 2002 Mar-Apr;25(2):111-4
Abstract
SUMMARY: Excessive daytime sleepiness (EDS) may limit the symptomatic treatment of Parkinson's disease and can alter the patient's lifestyle significantly. Ten consecutive patients with Parkinson's disease on various dopaminergic drugs and EDS were recruited to a 4-week open-label trial of modafinil. Patients were evaluated using the Epworth Sleepiness Scale and Unified Parkinson's Disease Rating Scale part III. All but three patients, with previous history of intolerability of a dopamine agonist caused by EDS, remained on their baseline medications. Modafinil was titrated as needed to a maximum of 400 mg/day. The mean Epworth Sleepiness Scale score at baseline of patients completing the study (n = 9) was 14.22 (+/- 3.03). After completing the study on an average dose of 172 mg/day, the Epworth Sleepiness Scale score was 6.0 (+/- 4.87). Unified Parkinson's Disease Rating Scale scores were not affected by this medication. Side effects encountered were headache, generalized paresthesias, and hallucinations (n = 1 each, the patient developing hallucinations dropped out of the trial before completing 4 weeks of the study drug). The three patients who did not tolerate any increments of dopamine agonist before modafinil were able to tolerate further upward titration of the dopamine agonist. Modafinil may be effective in reducing EDS in patients with Parkinson's disease treated with dopaminergic drugs. It does not seem to worsen parkinsonian symptoms and may allow further increase in dopaminergic therapy in patients previously unable to tolerate this because of EDS.
|
Home | to
Order |
1. Modafinil augmentation
of antidepressant treatment
2. Modafinil children
with attention-deficit/hyperactivity disorder
3. Modafinil in
fibromyalgia treatment
4. Modafinil
efficacy in narcolepsy
5. Modafinil narcolepsy:
symptoms and management
6. Modafinil successful
treatment of hypersomnia & narcolepsy
7. Modafinil
drug of choice for narcolepsy
8. Modafinil
in the treatment of
narcolepsy
9. Modafinil
effect on narcolepsy
10. Modafinil
a narcolepsy study
11. Modafinil
switching from narcolepsy drugs to modafinil
12. Modafinil
and naps as counter measures in sleep deprivation
13. Modafinil
as a treatment for excessive daytime sleepiness
14. Modafinil
use in a sleep deprivation experiment
15. Modafinil excessive sleepiness in Parkinson's disease
16. Modafinil the
unique properties of a new stimulant
17. Modafinil for
sustaining the alertness of helicopter pilots
18. Modafinil dosage
and safety
19. Modafinil
treatment of alcoholic organic brain syndrome
20. Modafinil
effect on melatonin, cortisol, and growth hormone
21. Modafinil
in obstructive sleep apnea-hypopnea syndrome
22. Modafinil
vs dextroamphetamine in treatment of adult ADHD
23. Modafinil
dopaminergic transmission mediates CNS stimulants
24. Modafinil
for daytime sleepiness in sleep apnea
25. Modafinil
treatment of residual excessive daytime sleepiness
26. Modafinil
amplification of cortical serotonin release
27. Modafinil for the treatment of
multiple sclerosis
